STAT

Opinion: Reinvent scientific publishing with blockchain technology

Blockchain-based publishing can give researchers and research institutions — not for-profit publishers — full control over the life cycle of scholarly publications.

If the open flow of scientific information is a fundamental part of science, then the scientific community is in trouble. Academic publishers, which dominate scientific publishing, reap great financial rewards from the work done by scientists, who are often frustrated and handcuffed by the process. I believe that blockchain technology, if harnessed correctly, can enable the change the industry sorely needs. This instrument of transparency can return the power of science to scientists, giving them unprecedented levels of control over their work.

A Deutsche Bank report once described the “bizarre triple-pay system” of scientific publishing. It works like this: Scientists, funded by governments out of taxpayers’ dollars, do research and write articles about it under their own direction, and then give them to. Although publishers pay scientific editors to review those articles, most of the work, such as the peer-review process of checking scientific validity and evaluating experiments, is done by scientist volunteers. Publishers then sell the articles to government-funded institutions, universities, and individuals at exorbitant prices, to be read by scientists, who are the ones who created those articles in the first place.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About FDA Dithering On Pharma Patents, WHO Pandemic Talks, And More
When it comes to a crucial controversy over patents for drug-and-device combination products, the FDA has been MIA.
STAT1 min read
STAT+: Element Biosciences, An Illumina Rival, On Its Genomics Ambitions — And Why It Hasn’t Gone Public
Element Biosciences' modest growth comes at a time when some other players are struggling in a sequencer market dominated by Illumina.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Boy Dying In Pfizer Trial; AstraZeneca Yanking Covid Shot, And More
A young boy died in a clinical trial for an experimental Pfizer gene therapy for Duchenne muscular dystrophy, about a year after receiving the therapy.

Related Books & Audiobooks